Industry News

Pharmaceutical Industry News

As Amgen strives to become the top…

June 7th, 2026|Fierce Pharma|

As Amgen strives to become the top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions in New Orleans this past

The FDA is going forward with…

June 5th, 2026|Fierce Pharma|

The FDA is going forward with an investigation into the safety of the abortion pill mifepristone, an initiative that could allow the Trump administration to impose restrictions on its use, The Wall Street Journal reports.

Each year, the global oncology…

June 5th, 2026|Fierce Pharma|

Each year, the global oncology community descends on Chicago for ASCO, where buzzy data drops, practice-changing posters and packed sessions offer a look at where cancer care is headed next. In this week’s episode of

With a resounding unanimous vote,…

June 4th, 2026|Fierce Pharma|

With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.

The drumbeat of news regarding…

June 4th, 2026|Fierce Pharma|

The drumbeat of news regarding Asian pharma—and particularly China—continues to grow louder. At the American Society of Clinical Oncology (ASCO) meeting, Akeso took center stage with an ivonescimab presentation, and Fierce’s Angus Liu took a

The platform was built in…

June 4th, 2026|Fierce Pharma|

The platform was built in collaboration with Vertex Pharmaceuticals, a biopharma company that launched a non-opioid pain reliever in early 2025.

Three times as many deaths in the…

June 4th, 2026|Fierce Pharma|

Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market since

The company inked another…

June 4th, 2026|Fierce Pharma|

The company inked another settlement with a prospective generic maker, leaving no further pending patent litigation for its Sunosi on the table.

Medical device distribution giant…

June 4th, 2026|Fierce Pharma|

Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the presence of toxic bacteria in

In response to a planned…

June 3rd, 2026|Fierce Pharma|

In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least

As its ultra-rare disease med…

June 3rd, 2026|Fierce Pharma|

As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the potential to convert the American treatment landscape for Niemann-Pick disease type C into one resembling

Cencora and Gilead have expanded…

June 3rd, 2026|Fierce Pharma|

Cencora and Gilead have expanded their longstanding partnership, cutting a deal in which the distribution giant will support access to the CAR-T cancer therapies Yescarta and Tecartus.

There were 487 booths at the…

June 3rd, 2026|Fierce Pharma|

There were 487 booths at the American Society of Clinical Oncology (ASCO)’s 2026 annual meeting in Chicago’s McCormick Place. Fierce Pharma Marketing attempted to see them all.

The words used to describe disease…

June 3rd, 2026|Fierce Pharma|

The words used to describe disease can shape how patients are diagnosed, treated and understood. From mpox to obesity to the Fitzpatrick scale, outdated or imprecise language can deepen stigma and obscure the full scope

The FDA has hit QOL Medical with…

June 3rd, 2026|Fierce Pharma|

The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug.

In 2017, a little-known company…

June 2nd, 2026|Fierce Pharma|

In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that would become Carvykti, and single-handedly

The drugmaker has issued a June 8…

June 2nd, 2026|Fierce Pharma|

The drugmaker has issued a June 8 ultimatum to an unspecified number of hospitals that have resisted a data submission policy it implemented in February. Furious hospital industry groups are pushing back, calling the decision

A nonprofit has launched to change…

June 2nd, 2026|Fierce Pharma|

A nonprofit has launched to change how endometriosis is researched, treated and understood, starting with a documentary that features the stories of people including, Amy Schumer and Marilyn Monroe.